Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05476679 · ClinicalTrials.gov registry record · Phase 1
Evaluation the Effects of Various Treatments on RZL-012-Induced Adverse Events
A Phase 1 study, sponsored by Raziel Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT05476679: Completed Phase 1 study, sponsored by Raziel Therapeutics.
NCT05476679 is a Phase 1 study that has completed, run by Raziel Therapeutics. The registered enrollment target is 48 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (20% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05476679, a Phase 1 study, has completed, sponsored by Raziel Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
This is a Phase 2, open-label, 2-stage, adaptive-design study in which subjects will be randomized into one of 5 treatment groups comprised of RZL-012 with or without additional study treatments:
Primary Outcome
Number of subjects with severe swelling in each subgroup
Interventions
- DRUG RZL-012
- DRUG RZL-012+Lidacaine injection prior treatment
- DRUG RZL-012+Medrol
- DRUG RZL-012+Celecoxib+Zyrtec
- DRUG RZL-012+facial and neck wrap
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2022-09-25 |
| Est. Completion | 2023-06-12 |
| Phase | Phase 1 |
What the finished NCT05476679 record still lists
NCT05476679 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (20% lower).
The record links to 0 conditions, and to 5 interventions - of which RZL-012 is the first listed.
NCT05476679 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05476679 about?
NCT05476679 is a clinical study titled "Evaluation the Effects of Various Treatments on RZL-012-Induced Adverse Events". This is a Phase 2, open-label, 2-stage, adaptive-design study in which subjects will be randomized into one of 5 treatment groups comprised of RZL-012 with or without additional study treatments:
What is the current status of trial NCT05476679?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2022-09-25. Estimated completion is 2023-06-12.
What interventions are being tested in trial NCT05476679?
The interventions under investigation include: RZL-012 (DRUG), RZL-012+Lidacaine injection prior treatment (DRUG), RZL-012+Medrol (DRUG), RZL-012+Celecoxib+Zyrtec (DRUG), RZL-012+facial and neck wrap (DRUG).
Who is sponsoring clinical trial NCT05476679?
This trial is sponsored by Raziel Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05476679's enrollment target sits among peer trials
48 1025th of 2000 higher than 948 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI